DOI: 10.12890/2024_004886

Respiratory alkalosis as an adverse effect of safinamide?

Authors

  • Flávia Freitas Internal Medicine Department, Unidade Local de Saúde Barcelos/Esposende, Barcelos, Portugal
  • Beatriz Rosa Internal Medicine Department, Unidade Local de Saúde Barcelos/Esposende, Barcelos, Portugal
  • Catarina Pinto Silva Internal Medicine Department, Unidade Local de Saúde Barcelos/Esposende, Barcelos, Portugal
  • Cristina Marques Internal Medicine Department, Unidade Local de Saúde Barcelos/Esposende, Barcelos, Portugal
  • João Mota Internal Medicine Department, Unidade Local de Saúde Barcelos/Esposende, Barcelos, Portugal
  • Carla Lemos Costa Internal Medicine Department, Unidade Local de Saúde Barcelos/Esposende, Barcelos, Portugal
  • Carlos Oliveira Internal Medicine Department, Unidade Local de Saúde Barcelos/Esposende, Barcelos, Portugal

flaviafreitas22@gmail.com

Keywords

Respiratory alkalosis, safinamide, Parkinson’s disease

Abstract

Respiratory alkalosis is associated with central nervous system (CNS) diseases, drugs, lung diseases and others. Safinamide is a recent anti-parkinsonian drug with anti-dyskinetic properties and a good adjunct to L-dopa therapy during the activation period, with no significant adverse effects described. The authors present a case of a 71-year-old woman, with Parkinson’s disease treated with levodopa/benserazide, safinamide, amitriptyline, sertraline and diazepam. She made multiple visits to the emergency department due to progressive dyspnoea and asthenia, with primary respiratory alkalosis, which was thought to be caused by anxiety-induced hyperventilation and treated accordingly. After a comprehensive study, it was determined that the most probable cause of the respiratory alkalosis was pharmacological. There was a clinical and temporal agreement with the introduction of safinamide.

View the entire article

Downloads

References

  1. Palmer BF, Clegg DJ. Respiratory Acidosis and Respiratory Alkalosis: Core Curriculum 2023. Am J Kidney Dis 2023;82:347–359
  2. Krapf R, Hulter HN. Respiratory alkalosis. In: Gennari FJ, Adrogue HJ, Editors. Acid-Base Disorders and Their Treatment (1st ed.), CRC Press; 2005, p. 641–679.
  3. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I Roberts EA et al. A method of estimating the probability of adverse drug reactions. Clin.Pharmacol Ther 1981;30:239-245.
  4. Giossi R, Carrara F, Mazzari M, Lo Re F, Senatore M, Schicchi A, et al. Overall Efficacy and Safety of Safinamide in Parkinson’s Disease: A Systematic Review and a Meta-analysis. Clin Drug Investig 2021;41:321–339.
  5. Lewis RA, Howell JB. Definition of the hyperventilation syndrome. Bull Eur Physiopathol Respir 1986;22:201-205.
  6. Boulding R, Stacey R, Niven R, Fowler SJ. Dysfunctional breathing: a review of the literature and proposal for classification. Eur Respir Ver 2016;25:287-94.
  7. Sadlon A, Chaitow L. Hyperventilation Syndrome/Breathing Pattern Disorders. In: Pizzorno JE, Murray MT editors. (2020). Textbook of Natural Medicine (5th ed.), Elsevier Enhanced Digital Version; 2020, p. 999-1008.

Published

2024-10-07

How to Cite

1.
Freitas F, Rosa B, Pinto Silva C, Marques C, Mota J, Lemos Costa C, et al. Respiratory alkalosis as an adverse effect of safinamide? . EJCRIM [Internet]. 2024 Oct. 7 [cited 2026 Nov. 3];11(11). Available from: https://ejcrim.com/index.php/ejcrim/article/view/4886

Most read articles by the same author(s)